Carol Ashe
Vermögen: - $ am 31.05.2026
Vermögen: - $ am 31.05.2026
Carol G.
Ashe currently works at Elicio Therapeutics, Inc. (United States), as Independent Director from 2020, Elicio Therapeutics, Inc., as Independent Director from 2020, and New York Genome Center, as Chief Business Officer from 2014.
Ms. Ashe also formerly worked at Aptose Biosciences, Inc., as Independent Director from 2018 to 2025, Endo International Plc, as Vice President-Corporate Development from 2011 to 2013, GSK Equity Investments Ltd, as Partner from 2009 to 2010, and GSK Plc, as Head-US Corporate Legal Group from 2007 to 2008.
Ms. Ashe received her undergraduate degree from The Pennsylvania State University and graduate degree from Villanova University School of Law.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 09.04.2026 | 0 ( -.--% ) | - $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| ELICIO THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.08.2020 |
New York Genome Center
New York Genome Center Miscellaneous Commercial ServicesCommercial Services Provides genomic research services | Corporate Officer/Principal | 01.01.2014 |
Elicio Therapeutics, Inc. (United States)
Elicio Therapeutics, Inc. (United States) BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops novel immunotherapies for treatment of cancer and other diseases | Direktor/Vorstandsmitglied | 01.01.2020 |
| Unternehmen | Position | Ende |
|---|---|---|
| APTOSE BIOSCIENCES INC. | Direktor/Vorstandsmitglied | 16.06.2025 |
| ENDO INTERNATIONAL PLC | Corporate Officer/Principal | 01.01.2013 |
GSK Equity Investments Ltd.
GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity invests in companies located in the United States and United kingdom. The firm targets companies operating in the field of biotechnology sector. It provides financing for early stage capital requirements. | Private Equity Investor | 30.03.2010 |
| GSK PLC | Corporate Officer/Principal | 01.01.2008 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 9 |
|---|---|
Aptose Biosciences, Inc.
Aptose Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Discovers, research and develops anticancer therapies with high safety profiles | Health Technology |
Elicio Therapeutics, Inc. (United States)
Elicio Therapeutics, Inc. (United States) BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops novel immunotherapies for treatment of cancer and other diseases | Health Technology |
Endo International Plc
Endo International Plc Pharmaceuticals: MajorHealth Technology Develops and manufactures immunology, urology, hepatology, generics & sterile injectables therapeutics products | Health Technology |
GSK Equity Investments Ltd.
GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity invests in companies located in the United States and United kingdom. The firm targets companies operating in the field of biotechnology sector. It provides financing for early stage capital requirements. | Finance |
GSK Plc
GSK Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes vaccines and other pharmaceutical products | Health Technology |
The Pennsylvania State University
The Pennsylvania State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
New York Genome Center
New York Genome Center Miscellaneous Commercial ServicesCommercial Services Provides genomic research services | Commercial Services |
Villanova University School of Law
Villanova University School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc. BiotechnologyHealth Technology Develops cancer immunotherapies | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen